|
|
Article: Molecular Insight Pharmaceuticals and University of Maryland Share NIH Grant.
- Article from:
- Business Wire
- Article date:
- August 26, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Research to Develop Radiopharmaceuticals for Monitoring Activity of ACE inCongestive Heart Failure
Molecular Insight Pharmaceuticals, Inc. announced new funding from the National Institutes of Health (NIH) to develop a novel class of molecular imaging pharmaceuticals to detect and non-invasively monitor the activity of angiotensin-converting enzyme (ACE) in patients with congestive heart failure. The research will be conducted jointly by the company and the Nuclear Medicine Division of the University of Maryland School of Medicine.
"Although the U.S. spends over $7 billion a year for ACE-inhibition therapy to control high blood ...